Matteo Morotti

Gynaecologist, Clinician Scientist. Supporter @genoacfc 🇮🇹➡️🏴󠁧󠁢󠁥󠁮󠁧󠁿➡️🇨🇭Tweets my own

[gilberto lopes @GlopesMd]

Top lung cancer developments in 2025?

My take:
2025 wasn’t about a single disruptive moment. It was about consolidation, maturation, and a few long-awaited signals finally turning solid.

1) MARIPOSA delivers OS
Amivantamab + lazertinib demonstrates an overall survival benefit over osimertinib in first-line EGFR-mutant NSCLC. Toxicity, logistics, and sequencing still matter—but this is now a real OS-based conversation, not just a PFS debate.

2) FLAURA2 confirms upfront intensification can matter
Osimertinib + chemotherapy shows improved OS vs osimertinib alone. Reinforces that combination strategies can deepen benefit, at the cost of complexity and tolerability. “Best first-line EGFR strategy” is now legitimately plural.

3) HER2 finally matters clinically
Accelerated approvals for zongertinib and sevabertinib in HER2-mutant NSCLC. Oral TKIs, meaningful response rates, and a credible path beyond antibody-drug conjugates alone.

4) EGFR exon 20 keeps inching forward
Sunvozertinib approved post-platinum. Incremental progress, but still meaningful in a historically difficult molecular subset.

5) c-MET ADC enters routine practice
Telisotuzumab vedotin approved for MET-high NSCLC. Expression-based biomarkers and ADCs are now firmly embedded in lung cancer decision-making.

6) A genuine advance in SCLC
Tarlatamab converts to full approval in platinum-refractory ES-SCLC with a survival benefit. Rare, and important.

7) Companion diagnostics become unavoidable
HER2 TKD, EGFR exon 20, MET expression—therapy is increasingly inseparable from the assay used to define eligibility. Testing strategy is now a core clinical decision.

8) Combination immunotherapy reality check
ATR inhibition + durvalumab misses OS (LATIFY). A reminder that biological plausibility still has to survive Phase 3.

9) AI moves from novelty to infrastructure
Improved CT nodule detection, risk stratification, and workflow support. Still assistive, not autonomous—but no longer theoretical.

10) Direction of travel is clear
More rare targets, more ADCs, OS gains in EGFR-mutant disease, slow but meaningful progress in SCLC—and increasing pressure on systems to deliver precision care at scale.

Bottom line: 2025 didn’t reinvent lung cancer. It made several long-promised ideas finally defensible at the OS level. That’s quieter progress—but it’s the kind that lasts.

#LCSM @SylvesterCancer @IASLC @myESMO @lungoncdoc @Latinamd @COlazagasti @Jani_Chinmay @NarjustFlorezMD @DrJNaidoo @StephenVLiu @EddieSantosMD @RManochakian @LuisRaezMD @uicc

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

ctDNA analysis in the CALGB/SWOG 80702 @JAMAOnc (presented at #GI25)
✅CALGB/SWOG 80702: Adjuvant FOLFOX ± celecoxib for stage III colon cancer
✅Adding celecoxib improved DFS & OS in ctDNA+patients, irrespective of PIK3CA mutational status (no benefit in ctDNA-)
👉Does ctDNA supersede PIK3CA status as a biomarker? Validation warranted.

https://t.co/432aQSDxrO
@OncoAlert

[Team Ovary, Memorial Sloan Kettering Cancer Center @TeamOvary_MSK]

New Team Ovary study out in Gynecologic Oncology! 🎉
Adding nivolumab to neoadjuvant chemo in advanced ovarian cancer was safe & feasible — 75% achieved complete resection.
Read here 👉 https://t.co/r1BgShDgb4

[Adam Grippin @adam_grippin]

🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators. https://t.co/sH13agsz5c

[Matteo Morotti @MMorotti]

@bettafiorito il clima sta diventando freddino in italia..non so
se sia l’inverno o è colpa di hamas..

[Matteo Morotti @MMorotti]

@RossiMario9640 @NicolaPorro Grazie, belle parole! esistono frange antisemite sia a destra che a sinistra, ma e’ un fatto che gli ebrei vennero mandati ad Auschwitz dai fascisti. In italia spero non accadrà più, grazie anche alla Costituzione antifascista, quella che permette agli sfigati come te di parlare.

[Matteo Morotti @MMorotti]

@Cris_CHML se lo dice la chri allora siamo tutti d’accordo..

[Matteo Morotti @MMorotti]

@StefanoPutinati Credo si scriva attaccato. Capisco che per gli universitari italiani l’educazione non esista più, ma almeno l’italiano…

[Matteo Morotti @MMorotti]

@GonzatoA quelli da cui il parrucchiere ci vanno…😆

[Matteo Morotti @MMorotti]

@fratotolo2 ah ma ci sono le macerie allora?

[Matteo Morotti @MMorotti]

@bettafiorito ‘Pronte per essere inviate’ vuol dire che non sono ancora state inviate, giusto? dov’è la contraddizione? O magari capisco male l’italiano… Capisco anche che a qualcuno possa dispiacere, ma ben venga se gli aiuti possono finalmente entrare!!

[Matteo Morotti @MMorotti]

@EsercitoCrucian l’avresti voluto più lungo quel tappeto?

[Matteo Morotti @MMorotti]

@drndbl si meglio seguire il tuo blog

[Matteo Morotti @MMorotti]

@angelica_albi perché erano tutti a seguire il tuo blog di geopolitica

[Matteo Morotti @MMorotti]

@MT_Meli_ verra a giocare a briscola a casa della campionessa d’eleganza

[Matteo Morotti @MMorotti]

@fratotolo2 @SalisIlaria colpa del voto segreto della santanche!!! maledetti franchi tiratori…

[Matteo Morotti @MMorotti]

@NicolaPorro la santanche???

[Matteo Morotti @MMorotti]

@matteosalvinimi era anche una delle poche volte che ti presenti in parlamento😩…mai una gioia per il nostro ministro..stai diventando lo ‘iettatore’ di pirandello…il Chiarchiaro della politica..

[Matteo Morotti @MMorotti]

@EsercitoCrucian quanti ne ha fatti cruciani?